Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Support Care Cancer
Asıl Yazarlar: Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127871/
https://ncbi.nlm.nih.gov/pubmed/27557833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-016-3388-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller